Sorafenib: activity and clinical application in patients with hepatocellular carcinoma

Bibliography

• Sandhu DS, Tharayil VS, Lai JP, Roberts LR. Treatment options for hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 2008;2:81-92
   PubMedGoogle Scholar
• Cormier JN, Thomas KT, Chari RS, Pinson CW. Management of hepatocellular carcinoma. J Gastrointest Surg 2006;10:761-80
   PubMed Web of Science ®Google Scholar
• Poon RT, Fan ST, Tsang FH, Wong J. Locoregional therapies for hepatocellular carcinoma: a critical review from the surgeon's perspective. Ann Surg 2002;235:466-86
   PubMed Web of Science ®Google Scholar
• Rayya F, Harms J, Bartels M, Results of resection and transplantation for hepatocellular carcinoma in cirrhosis and noncirrhosis. Transplant Proc 2008;40:933-5
   PubMedGoogle Scholar
• Chaparro M, Gonzalez Moreno L, Trapero-Marugan M, Review article: pharmacological therapy for hepatocellular carcinoma with sorafenib and other oral agents. Aliment Pharmacol Ther 2008;28:1269-77
   PubMed Web of Science ®Google Scholar
• Ng R, Chen EX. Curr. Sorafenib (BAY 43-9006): review of clinical development. Clin Pharmacol 2006;1:223-8
   Google Scholar
• Caraglia M, Tassone P, Marra M, Targeting Raf-kinase: molecular rationales and translational issues. Ann Oncol 2006;17(Suppl 7):vii124-127
   PubMedGoogle Scholar
• Chia WJ, Tang BL. Emerging roles for Rab family GTPases in human cancer. Biochim Biophys Acta 2009;1795:110-16
   PubMed Web of Science ®Google Scholar
• Papageorge AG, Defeo-Jones D, Robinson P, Mol. Saccharomyces cerevisiae synthesizes proteins related to the p21 gene product of ras genes found in mammals. Cell Biol 1984;4:23-9
   Google Scholar
• Williams NG, Roberts TM. Signal transduction pathways involving the Raf proto-oncogene. Cancer Metastasis Rev 1994;13:105-16
   PubMed Web of Science ®Google Scholar
• Wong KK. Recent developments in anti-cancer agents targeting the Ras/Raf/ MEK/ERK pathway. Recent Pat Anticancer Drug Discov 2009;4:28-35
   PubMed Web of Science ®Google Scholar
• Rubinfeld H, Seger R. The ERK cascade: a prototype of MAPK signaling. Mol Biotechnol 2005;31:151-74
   PubMed Web of Science ®Google Scholar
• Boulton TG, Nye SH, Robbins DJ, ERKs: a family of protein-serine/threonine kinases that are activated and tyrosine phosphorylated in response to insulin and NGF. Cell 1991;65:663-75
   PubMed Web of Science ®Google Scholar
• Cobb MH, Hepler JE, Cheng M, Robbins D. The mitogen-activated protein kinases, ERK1 and ERK2. Semin Cancer Biol 1994;5:261-8
   PubMed Web of Science ®Google Scholar
• Grammer TC, Blenis J. Evidence for MEK-independent pathways regulating the prolonged activation of the ERK-MAP kinases. Oncogene 1997;14:1635-42
   PubMed Web of Science ®Google Scholar
• Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 2007;26:3291-310
   PubMed Web of Science ®Google Scholar
• Friday BB, Adjei AA. Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy. Clin Cancer Res 2008;14:342-6
   PubMed Web of Science ®Google Scholar
• Ria R, Vacca A, Russo F, A VEGF-dependent autocrine loop mediates proliferation and capillarogenesis in bone marrow endothelial cells of patients with multiple myeloma. Thromb Haemost 2004;92:1438-45
   PubMed Web of Science ®Google Scholar
• Keating GM, Santoro A. Sorafenib: a review of its use in advanced hepatocellular carcinoma. Drugs 2009;69:223-40
   PubMed Web of Science ®Google Scholar
• Gollob JA, Wilhelm S, Carter C, Kelley SL. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway. Semin Oncol 2006;33:392-406
   PubMed Web of Science ®Google Scholar
• Ueda M, Toji E, Nunobiki O, Mutational analysis of the BRAF gene in human tumor cells. Hum Cell 2008;21:13-7
   PubMed Web of Science ®Google Scholar
• Halilovic E, Solit DB. Therapeutic strategies for inhibiting oncogenic BRAF signaling. Curr Opin Pharmacol 2008;8:419-26
   PubMed Web of Science ®Google Scholar
• Kane RC, Farrell AT, Madabushi R, Sorafenib for the treatment of unresectable hepatocellular carcinoma. Oncologist 2009;14:95-100
   PubMed Web of Science ®Google Scholar
• Jacob K, Sollier C, Jabado N. Circulating tumor cells: detection, molecular profiling and future prospects. Expert Rev Proteomics 2007;4:741-56
   PubMed Web of Science ®Google Scholar
• Rozengurt E. Mol. Growth factors, cell proliferation and cancer: an overview. Biol Med 1983;1:169-81
   Google Scholar
• Strumberg D. Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment. Drugs Today (Barc) 2005;41:773-84
   PubMed Web of Science ®Google Scholar
• Strumberg D, Clark JW, Awada A, Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist 2007;12:426-37
   PubMed Web of Science ®Google Scholar
• Minami H, Kawada K, Ebi H, Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors. Cancer Sci 2008;99:1492-8
   PubMed Web of Science ®Google Scholar
• Akaza H, Tsukamoto T, Murai M, Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma. Jpn J Clin Oncol 2007;37:755-62
   PubMed Web of Science ®Google Scholar
• Lencioni R, Marrero J, Venook A, Design and rationale for the non-interventional Global Investigation of Therapeutic DEcisions in Hepatocellular Carcinoma and Of its Treatment with Sorafenib (GIDEON) study. Int J Clin Pract 2010;64(8):1034-41
   PubMedGoogle Scholar
• Llanos L, Bellot P, Zapater P, Acute hepatitis in a patient with cirrhosis and hepatocellular carcinoma treated with sorafenib. Am J Gastroenterol 2009;104:257-8
   PubMed Web of Science ®Google Scholar
• Wei L, Huang N, Yang L, Sorafenib reverses multidrug resistance of hepatoma cells in vitro. Nan Fang Yi Ke Da Xue Xue Bao 2009;29:1016-19
   PubMedGoogle Scholar
• Rahmani M, Davis EM, Bauer C, Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation. J Biol Chem 2005;280:35217-27
   PubMed Web of Science ®Google Scholar
• Reynolds JE, Yang T, Qian L, Mcl-1, a member of the Bcl-2 family, delays apoptosis induced by c-Myc overexpression in Chinese hamster ovary cells. Cancer Res 1994;54:6348-52
   PubMed Web of Science ®Google Scholar
• Liu L, Cao Y, Chen C, Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 2006;66:11851-8
   PubMed Web of Science ®Google Scholar
• Wei L, Su N, Zheng DY, Reversion of drug-resistant hepatocellular carcinoma cell line BEL-7402/FU by sorafenib. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 2009;25:344-7
   PubMedGoogle Scholar
• Shiota M, Eto M, Yokomizo A, Sensitivity of doxorubicin-resistant cells to sorafenib: possible role for inhibition of eukaryotic initiation factor-2alpha phosphorylation. Int J Oncol 2010;37(2):509-17
   PubMedGoogle Scholar
• Wilhelm SM, Adnane L, Newell P, Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 2008;7:3129-40
   PubMed Web of Science ®Google Scholar
• Yau T, Chan P, Epstein R, Poon RT. Management of advanced hepatocellular carcinoma in the era of targeted therapy. Liver Int 2009;29:10-17
   PubMed Web of Science ®Google Scholar
• Moore M, Hirte HW, Siu L, Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. Ann Oncol 2005;16:1688-94
   PubMed Web of Science ®Google Scholar
• Richly H, Kupsch P, Passage K, Results of a phase I trial of BAY 43-9006 in combination with doxorubicin in patients with primary hepatic cancer. Int J Clin Pharmacol Ther 2004;42:650-1
   PubMedGoogle Scholar
• Abou-Alfa GK, Schwartz L, Ricci S, Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006;24:4293-300
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90
   PubMed Web of Science ®Google Scholar
• Cheng AL, Kang YK, Chen Z, Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25-34
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK. Selection of patients with hepatocellular carcinoma for sorafenib. J Natl Compr Canc Netw 2009;7:397-403
   PubMed Web of Science ®Google Scholar
• Sorafenib. gastrointestinal perforation. Prescrire Int 2009;18:69 PMID: 19585726
   Google Scholar
• Batist G, Ramakrishnan G, Rao CS, Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol 2001;19:1444-54
   PubMed Web of Science ®Google Scholar
• Almhanna K, Philip PA. Safety and efficacy of sorafenib in the treatment of hepatocellular carcinoma. Onco Targets Ther 2009;2:261-7
   PubMed Web of Science ®Google Scholar
• Cannistra SA. Challenges and pitfalls of combining targeted agents in phase I studies. J Clin Oncol 2008;26:3665-7
   PubMed Web of Science ®Google Scholar
• Takimoto CH, Awada A. Safety and anti-tumor activity of sorafenib (Nexavar) in combination with other anti-cancer agents: a review of clinical trials. Cancer Chemother Pharmacol 2008;61:535-48
   PubMed Web of Science ®Google Scholar
• Li XM, Tang ZY, Qin LX, Serum vascular endothelial growth factor is a predictor of invasion and metastasis in hepatocellular carcinoma. J Exp Clin Cancer Res 1999;18:511-17
   PubMedGoogle Scholar
• Schoenleber SJ, Kurtz DM, Talwalkar JA, Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysis. Br J Cancer 2009;100:1385-92
   PubMed Web of Science ®Google Scholar
• Worns MA, Weinmann A, Schuchmann M, Galle PR. Systemic therapies in hepatocellular carcinoma. Dig Dis 2009;27:175-88
   PubMed Web of Science ®Google Scholar
• Chen FS, Cui YZ, Luo RC, Coadministration of sorafenib and cisplatin inhibits proliferation of hepatocellular carcinoma HepG2 cells in vitro. Nan Fang Yi Ke Da Xue Xue Bao 2008;28:1684-7
   PubMedGoogle Scholar
• Wu J, Luo RC, Zhang H, Cui YZ. Inhibitory effect of sorafenib combined with arsenic trioxide on hepatocellular carcinoma cells. Nan Fang Yi Ke Da Xue Xue Bao 2008;28:639-41
   PubMedGoogle Scholar
• Simpson D, Keating GM. Sorafenib: in hepatocellular carcinoma. Drugs 2008;68:251-8
   PubMed Web of Science ®Google Scholar
• Muszbek N, Shah S, Carroll S, Economic evaluation of sorafenib in the treatment of hepatocellular carcinoma in Canada. Curr Med Res Opin 2008;24:3559-69
   PubMed Web of Science ®Google Scholar
• Llovet JM, Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology 2008;48:1312-27
   PubMed Web of Science ®Google Scholar
• Kudo M. Hepatocellular carcinoma 2009 and beyond: from the surveillance to molecular targeted therapy. Oncology 2008;75(Suppl 1):1-12
   PubMedGoogle Scholar
• Duenas-Gonzalez A, Garcia-Lopez P, Herrera LA, The prince and the pauper. A tale of anticancer targeted agents. Mol Cancer 2008;7:82
   PubMed Web of Science ®Google Scholar
• Detry O, Delwaide J, De Roover A, Palliative management of hepatocarcinoma with sorafenib (Nexavar). Results of the SHARP study (sorafenib hepatocarcinoma assessment randomized protocol trial). Rev Med Liege 2009;64:168-70
   PubMedGoogle Scholar
• Pinter M, Sieghart W, Graziadei I, Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis. Oncologist 2009;14:70-6
   PubMed Web of Science ®Google Scholar
• Tremosini S, Reig M, de Lope CR, Treatment of early hepatocellular carcinoma: towards personalized therapy. Dig Liver Dis 2010;42(Suppl 3):S242-248
   PubMedGoogle Scholar
• Zender L, Villanueva A, Tovar V, Cancer gene discovery in hepatocellular carcinoma. J Hepatol 2010;52:921-9
   PubMed Web of Science ®Google Scholar
• Zucman-Rossi J. Molecular classification of hepatocellular carcinoma. Dig Liver Dis 2010;42(Suppl 3):S235-41
   PubMedGoogle Scholar
• Abrams P, Marsh JW. Current approach to hepatocellular carcinoma. Surg Clin North Am 2010;90:803-16
   PubMed Web of Science ®Google Scholar
• Yeganeh M, Finn RS, Saab S. Apparent remission of a solitary metastatic pulmonary lesion in a liver transplant recipient treated with sorafenib. Am J Transplant 2009;9:2851-4
   PubMed Web of Science ®Google Scholar
• Lencioni R, Marrero J, Venook A, Design and rationale for the non-interventional Global Investigation of Therapeutic DEcisions in Hepatocellular Carcinoma and Of its Treatment with Sorafenib (GIDEON) study. Int J Clin Pract 2010;64:1034-41
   PubMed Web of Science ®Google Scholar
• Yoon DH, Ryoo BY, Ryu MH, Sorafenib for recurrent hepatocellular carcinoma after liver transplantation. Jpn J Clin Oncol 2010;40:768-73
   PubMedGoogle Scholar
• Biolato M, Marrone G, Racco S, Transarterial chemoembolization (TACE) for unresectable HCC: a new life begins? Eur Rev Med Pharmacol Sci 2010;14:356-62
   PubMed Web of Science ®Google Scholar
• Zhao JD, Liu J, Ren ZG, Maintenance of Sorafenib following combined therapy of three-dimensional conformal radiation therapy/intensity-modulated radiation therapy and transcatheter arterial chemoembolization in patients with locally advanced hepatocellular carcinoma: a phase I/II study. Radiat Oncol 2010;5:12
   PubMedGoogle Scholar